DiaMedica TherapeuticsDMAC +1.75%31 FCF Yield % is -9.03 as of Jun. 24, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, DiaMedica Therapeutics ranks better than 50.95% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
DiaMedica Therapeutics FCF Yield % Related Terms
DiaMedica Therapeutics FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, DiaMedica Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (DMAC) has a FCF Yield % of -9.03 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #695 out of 1417 companies in the Biotechnology industry, placing it in the top 49%.
Is DiaMedica Therapeutics' FCF Yield % too high?
DiaMedica Therapeutics' current FCF Yield % is -9.03. Based on the distribution chart, DiaMedica Therapeutics ranks #695 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' FCF Yield % compare to BCYC and RZLT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #695 out of 1417 companies for FCF Yield %. This puts DiaMedica Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current FCF Yield % is -9.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current FCF Yield % of -9.03. The current FCF Yield % is -9.03. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current FCF Yield % is -9.03 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
